financetom
Business
financetom
/
Business
/
Dril-Quip to Merge With Innovex Downhole Solutions in All-Stock Deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dril-Quip to Merge With Innovex Downhole Solutions in All-Stock Deal
Mar 18, 2024 2:50 PM

05:27 PM EDT, 03/18/2024 (MT Newswires) -- Dril-Quip ( DRQ ) said Monday it agreed to merge with Innovex Downhole Solutions in an all-stock transaction.

Dril-Quip ( DRQ ) investor will own 52% of the combined company, and Innovex will have 48%.

Dril-Quip ( DRQ ) said funds affiliated with Amberjack Capital Partners hold a majority stake in Innovex and will own about 43% of the combined company.

The merged company will be named Innovex International, and its shares will trade on the New York Stock Exchange under the symbol INVX, Dril-Quip ( DRQ ) said.

Dril-Quip ( DRQ ) expects to close the deal in Q3. subject to regulatory clearances and approval by its shareholders. The combined company will be based in Houston.

Innovex Chief Executive Officer Adam Anderson will become CEO of the combined company, and Innovex Chief Financial Officer Kendal Reed will be CFO of the new entity.

In 2023, Dril-Quip ( DRQ ) had estimated revenue of $478 million, and Innovex had $556 million.

Dril-Quip ( DRQ ) shares rose 5.6% in recent after-hours trading.

Price: 25.05, Change: +1.32, Percent Change: +5.56

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results
Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results
May 14, 2024
Arcutis Biotherapeutics, Inc. ( ARQT ) reported its first-quarter financial results after the bell Tuesday. Here's a look at the highlights.  The Details: Arcutis Biotherapeutics ( ARQT ) reported quarterly earnings of 32 cents per share which beat the analyst consensus estimate of losses of 73 cents. Quarterly sales clocked in at $49.57 million, beating the analyst consensus estimate of...
Kyverna Therapeutics Q1 Loss Narrows
Kyverna Therapeutics Q1 Loss Narrows
May 14, 2024
05:09 PM EDT, 05/14/2024 (MT Newswires) -- Kyverna Therapeutics ( KYTX ) reported a Q1 net loss late Tuesday of $1.12 per diluted share, compared with a loss of $12.10 per share a year earlier. A single analyst polled by Capital IQ expected a loss of $0.80. No revenue was reported for the quarter ended March 31, as expected for...
Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours
Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours
May 14, 2024
05:08 PM EDT, 05/14/2024 (MT Newswires) -- Nuvation Bio ( NUVB ) reported a Q1 loss late Tuesday of $0.07 per diluted share, narrowing from the loss of $0.10 a year earlier. Analysts polled by Capital IQ expected a loss of $0.10. The company didn't report revenue, as expected by analysts surveyed by Capital IQ. As of March 31, the...
Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises
Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises
May 14, 2024
05:08 PM EDT, 05/14/2024 (MT Newswires) -- Poseida Therapeutics ( PSTX ) reported a Q1 loss late Tuesday of $0.25 per diluted share, narrowing from a loss of $0.45 a year earlier. Four of five analysts polled by Capital IQ expected a loss of $0.42. Revenue for the quarter ended March 31 was $28.1 million, compared with $10.3 million a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved